Garcia, Santos D.de Deus Fonticoba, TeresaCores, CarlosMunoz, GuillermoPaz Gonzalez, Jose M.Martinez Miro, CristinaSuarez, EsterJesus, SilviaAguilar, MiquelPastor, PauPlanellas, LluisCosgaya, MarinaGarcia Caldentey, JuanCaballol, NuriaLegarda, InesHernandez Vara, JorgeCabo, IriaLopez Manzanares, LuisGonzalez Aramburu, IsabelAvila Rivera, Maria A.Catalan, Maria J.Nogueira, VictorPuente, VictorRuiz de Arcos, MariaBorrue, CarmenSolano Vila, BertaAlvarez Sauco, MariaVela, LydiaEscalante, SoniaCubo, EstherCarrillo Padilla, FranciscoMartinez Castrillo, Juan C.Sanchez Alonso, PilarAlonso Losada, Maria G.Lopez Ariztegui, NuriaGaston, ItziarClavero, PedroKulisevsky, JaimeBlazquez Estrada, MartaSeijo, ManuelRuiz Martinez, JavierValero, CaridadKurtis, Monicade Fabregues, OriolGonzalez Ardura, JessicaOrdas, CarlosLopez Diaz, Luis M.McAfee, DarrianMartinez-Martin, PabloMir, PabloCOPPADIS Study Grp2025-01-072025-01-072021-12-16https://hdl.handle.net/10668/27942Quality of life (QOL) plays an important role in independent living in Parkinson's disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson's disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months +/- 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 >= 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 +/- 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 +/- 13 to 20.3 +/- 16.4; p = 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 +/- 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 +/- 13 to 20.3 +/- 16.4; p = 5 and >= 10 points of BDI-II and NMSS total score at V2 multiplied the probability of presenting clinically significant HRQoL impairment by 5 (OR = 5.453; 95% CI 1.663-17.876; p = 0.005) and 8 (OR = 8.217; 95% CI, 2.975-22.696; p = 0.002), respectively. In conclusion, age, gender, mood, and non-motor impairment were associated with clinically significant HRQoL impairment after the 2-year follow-up in PD patients.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Nonmotor symptomsGender-differencesImpactDisabilityQuestionnaireProgressionScaleDeterminantsValidationOnsetresearch article34916528open access10.1038/s41531-021-00256-w2373-8057https://www.nature.com/articles/s41531-021-00256-w.pdf730934900001